Bronchodilators Global Market is Projected to Increase Revenues Growth, Business Insights, Future Demand and Forecast 2024-2033 | Pfizer Inc., Bayer AG, Novartis AG, Cipla Limited, Amgen Inc.

"The Business Research Company has recently revised its global market reports, now incorporating the most current data for 2024 along with projections extending up to 2033.

Bronchodilators Global Market Report 2024 by The Business Research Company offers comprehensive market insights, empowering businesses with a competitive edge. It includes detailed estimates for numerous segments and sub-segments, providing valuable strategic guidance.

The Market Size Is Expected To Reach $43.25 billion In 2028 At A CAGR Of 7.0% :

The bronchodilators market size has grown strongly in recent years. It will grow from $30.43 billion in 2023 to $32.93 billion in 2024 at a compound annual growth rate (CAGR) of 8.2%. The growth in the historic period can be attributed to growing geriatric population, rising incidence of asthma, growing funding by government organizations, increase in ageing population, and increasing air pollution across the globe.

The bronchodilators market size is expected to see strong growth in the next few years. It will grow to $43.25 billion in 2028 at a compound annual growth rate (CAGR) of 7.0%. The growth in the forecast period can be attributed to increasing prevalence of COPD, rising awareness about lung diseases treatment aided with escalating research and development efforts, increase in prevalence of pulmonary disorders, the rise in disposable income, and increasing smoking rates. Major trends in the forecast period include advanced clinical research and innovative strategies, growing technological advancements, high prevalence of lung diseases such as COPD and asthma, new product launches, and rising number of patients with acute respiratory infections.

Request A Sample Of This Report - https://www.thebusinessresearchcompany.com/sample.aspx?id=13816&type=smp

Bronchodilators Market Major Segments
The bronchodilators market covered in this report is segmented -
1) By Type: Beta-Adrenergic Bronchodilators, Anticholinergic Bronchodilators, Xanthine Derivatives, Other Types
2) By Route of Administration: Oral, Nasal (Inhalation), Injectable
3) By Indication: Asthma, Chronic Obstructive Pulmonary Disease (COPD), Allergic Reactions, Breathing Problem, Other Indications
4) By End-User: Hospitals, Specialty Clinics, Other End Users

Key Driver - Rising COPD Prevalence Fuels Growth In Bronchodilator Market

The increasing prevalence of chronic obstructive pulmonary disease (COPD) is expected to propel the growth of the bronchodilator market going forward. Chronic obstructive pulmonary disease is a progressive lung disease characterized by chronic inflammation of the airways and obstruction or limitation of airflow. Bronchodilators are used in chronic obstructive pulmonary disease (COPD) to relax the muscles around the airways, which helps to open the airways and make it easier to breathe. For instance, in March 2023, according to a report by the Scottish Public Health Observatory, led by Public Health Scotland, a UK-based Population Health Centre, COPD rates started to increase as the impact of COVID-19 eased. The rate in males increased from 83.2 to 97.6 cases per 100,000, and for females, the increase was from 72.6 to 97.3. Therefore, the increasing prevalence of chronic obstructive pulmonary disease (COPD) is driving the growth of the bronchodilator market.

Customise This Report As Per Your Requirements - https://www.thebusinessresearchcompany.com/Customise?id=13816&type=smp

Prominent Trend - Lupin Introduces DIFIZMA A Groundbreaking Fixed-Dose Triple Drug Combination

Major companies operating in the bronchodilator market are developing innovative products such as fixed-dose triple-drug combinations to better serve patients. A fixed-dose triple drug combination is a medication that contains three active ingredients in a single formulation, with each ingredient having a predetermined dose. For instance, in January 2023, Lupin, an India-based pharmaceutical firm, launched DIFIZMA, a fixed-dose triple-drug bronchodilator with a combination of indacaterol, glycopyrronium, and mometasone for managing asthma. DIFIZMA is offered as a dry powder inhalation. DIFIZMA is the only fixed-dose combination that has been approved by the Drug Controller General of India (DCGI) for the treatment of inadequately controlled asthma by improving lung function, providing better symptom control, and reducing exacerbations.

Bronchodilators Market Players
Major companies operating in the bronchodilators market report are Pfizer Inc. , Johnson & Johnson Services Inc., F. Hoffmann-La Roche Ltd., Bayer AG, Novartis AG, Thermo Fisher Scientific, Abbott Laboratories , Sanofi S.A., GlaxoSmithKline plc, Siemens Healthcare GmbH, Merck & Co. Inc., AstraZeneca plc, Teva Pharmaceuticals Industries Ltd., Mylan N.V., Quest Diagnostics Incorporated., Boehringer Ingelheim International GmbH, Aurobindo Pharma Limited, Bio-Rad Laboratories Inc., Cipla Limited, Hikma Pharmaceutical plc, Amneal Pharmaceuticals LLC, Glenmark Pharmaceuticals Limited, Vectura Group Limited, Foundation Medicine Inc., Sun Pharmaceutical Industries Ltd., Amgen Inc., Kissei Pharmaceutical Co.Ltd., Mitsubishi Tanabe Pharma, Theron Pharmaceuticals, Viatris Inc.

View The Full Report Here - https://www.thebusinessresearchcompany.com/report/bronchodilators-global-market-report

Largest And Fastest Growing Region In The Market
North America was the largest region in the bronchodilators market in 2023. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the bronchodilators market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.

The Table Of Content For The Market Report Include:
1. Executive Summary
2. Bronchodilators Market Report Structure
3. Bronchodilators Market Trends And Strategies
4. Bronchodilators Market - Macro Economic Scenario
5. Bronchodilators Market Size And Growth
…..
27. Bronchodilators Market Competitor Landscape And Company Profiles
28. Key Mergers And Acquisitions
29. Future Outlook and Potential Analysis
30. Appendix

Contact Us:
The Business Research Company
Europe: +44 207 1930 708
Asia: +91 88972 63534
Americas: +1 315 623 0293
Email: info@tbrc.info

Follow Us On:
LinkedIn: https://in.linkedin.com/company/the-business-research-company
Twitter: https://twitter.com/tbrc_info
YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ

Learn More About The Business Research Company
The Business Research Company (www.thebusinessresearchcompany.com) is a leading market intelligence firm renowned for its expertise in company, market, and consumer research. With a global presence, TBRC's consultants specialize in diverse industries such as manufacturing, healthcare, financial services, chemicals, and technology, providing unparalleled insights and strategic guidance to clients worldwide.

This release was published on openPR.